Bill
Bill > HR971
US HR971
Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015
summary
Introduced
02/13/2015
02/13/2015
In Committee
02/20/2015
02/20/2015
Crossed Over
Passed
Dead
01/03/2017
01/03/2017
Introduced Session
114th Congress
Bill Summary
Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015 Amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to extend by six months the exclusivity period for an approved drug or biological product when the product is additionally approved to prevent, diagnose, or treat a new indication that is a rare disease or condition (also known as an "orphan disease"). Allows the FDA to revoke an extension if the application for the new indication contained an untrue material statement. Requires the sponsor of a product receiving an extension to notify the FDA one year prior to discontinuing production for commercial reasons. Requires the FDA to notify the public of products that receive this extension and patents related to those products. Limits a product to one extension under this Act. Sets forth that extensions under this Act are in addition to other extensions. Applies only to products approved after enactment of this Act for a new indication that is a rare disease or condition.
Committee Categories
Business and Industry, Health and Social Services
Sponsors (22)
Gus Bilirakis (R)*,
Brad Ashford (D),
G. Butterfield (D),
Rodney Davis (R),
Michael Fitzpatrick (R),
Jeff Fortenberry (R),
Rodney Frelinghuysen (R),
Christopher Gibson (R),
Sam Graves (R),
Glenn Grothman (R),
Alcee Hastings (D),
Jared Huffman (D),
Leonard Lance (R),
Michael McCaul (R),
Cathy McMorris Rodgers (R),
Richard Nugent (R),
Erik Paulsen (R),
Bruce Poliquin (R),
Mike Quigley (D),
Dana Rohrabacher (R),
Steve Scalise (R),
Chris Smith (R),
Last Action
Referred to the Subcommittee on Health. (on 02/20/2015)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
Loading...